Roivant Sciences Ltd.
ROIV
71 insider filings · Latest: Oct 1, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Sale | 587,390 | $27.51 | $16.2M | 13,736,547(D) | View → |
| Feb 20, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Sale | 1,012,610 | $27.15 | $27.5M | 13,736,547(D) | View → |
| Feb 19, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Sale | 1,400,000 | $27.42 | $38.4M | 13,736,547(D) | View → |
| Feb 20, 2026 | Feb 20 9:29 PM | FRANK TORTI | Proposed Sale | 1,600,000 | $27.52 | $44.0M | — | View → |
| Feb 19, 2026 | Feb 19 9:24 PM | FRANK TORTI | Proposed Sale | 1,400,000 | $27.48 | $38.5M | — | View → |
| Feb 13, 2026 | Feb 18 10:57 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $26.49 | $5.3M | 1,654,597(D) | View → |
| Feb 13, 2026 | Feb 14 2:02 AM | Keith S ManchesterDirector | Sale | 375,784 | $26.50 | $10.0M | 15,127,329(I) | View → |
| Feb 12, 2026 | Feb 14 2:02 AM | Keith S ManchesterDirector | Sale | 425,000 | $26.75 | $11.4M | 15,503,113(I) | View → |
| Feb 11, 2026 | Feb 14 2:02 AM | Keith S ManchesterDirector | Sale | 425,000 | $26.67 | $11.3M | 15,928,113(I) | View → |
| Feb 13, 2026 | Feb 14 2:00 AM | Daniel Allen GoldDirector | Sale | 375,784 | $26.50 | $10.0M | 15,127,329(I) | View → |
| Feb 12, 2026 | Feb 14 2:00 AM | Daniel Allen GoldDirector | Sale | 425,000 | $26.75 | $11.4M | 15,503,113(I) | View → |
| Feb 11, 2026 | Feb 14 2:00 AM | Daniel Allen GoldDirector | Sale | 425,000 | $26.67 | $11.3M | 15,928,113(I) | View → |
| Feb 13, 2026 | Feb 14 1:45 AM | QVT Financial LPOther | Sale | 375,784 | $26.50 | $10.0M | 15,127,329(I) | View → |
| Feb 12, 2026 | Feb 14 1:45 AM | QVT Financial LPOther | Sale | 425,000 | $26.75 | $11.4M | 15,503,113(I) | View → |
| Feb 11, 2026 | Feb 14 1:45 AM | QVT Financial LPOther | Sale | 425,000 | $26.67 | $11.3M | 15,928,113(I) | View → |
| Feb 13, 2026 | Feb 13 9:21 PM | Venker Eric | Proposed Sale | 200,000 | $26.49 | $5.3M | — | View → |
| Feb 9, 2026 | Feb 11 10:53 PM | Mayukh SukhatmeDirector, President & CIO | Sale | 339,441 | $26.47 | $9.0M | 19,148,664(D) | View → |
| Feb 9, 2026 | Feb 9 9:13 PM | Sukhatme Mayukh | Proposed Sale | 339,441 | $26.47 | $9.0M | — | View → |
| Jan 12, 2026 | Jan 12 9:04 PM | Venker Eric | Proposed Sale | 200,000 | $21.92 | $4.4M | — | View → |
| Dec 31, 2025 | Dec 31 9:30 PM | Sukhatme Mayukh | Proposed Sale | 1,018,995 | $21.71 | $22.1M | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 500,000 | $3.85 | 14,724,363(D) | View → |
| Jun 24, 2026 | Jun 26 10:13 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,244,834(D) | View → |
| May 22, 2026 | May 22 10:25 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,444,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:27 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,644,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Richard PulikCFO | Grant/Award | 84,026 | $29.08 | 84,026(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Jennifer HumesChief Accounting Officer | Grant/Award | 27,157 | $29.08 | 27,157(D) | View → |
| Mar 30, 2026 | Apr 1 11:20 PM | Matthew GlineDirector, CEO | Option Exercise | 2,178,150 | — | 0(D) | View → |
| Mar 30, 2026 | Apr 1 11:19 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 1,306,889 | — | 0(D) | View → |
| Mar 26, 2026 | Mar 31 1:01 AM | Meghan FitzgeraldDirector | Option Exercise | 70,000 | $8.80 | 48,578(D) | View → |
| Mar 17, 2026 | Mar 19 10:36 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,844,834(D) | View → |
| Feb 23, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 587,390 | $3.85 | 3,026,184(D) | View → |
| Feb 20, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,012,610 | $3.85 | 3,613,574(D) | View → |
| Feb 19, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,400,000 | $3.85 | 4,626,184(D) | View → |
| Feb 13, 2026 | Feb 18 10:57 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 5,044,834(D) | View → |
| Feb 9, 2026 | Feb 11 10:53 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 651,558 | $12.68 | 0(D) | View → |
← Previous
Page 2 of 2